The University of Illinois College of Medicine Rockford fast-tracks final year medical students – WIFR

ROCKFORD, Ill. (WIFR) -- The University of Illinois College of Medicine Rockford fast-tracks final year medical students to help on the COVID-19 pandemic response.

Alex Stagnaro-Green is the regional dean for the college of medicine and says 44 out of the 54 fourth year medical students graduated early to fight the pandemic.

"Being able to graduate early, but also potentially then to make an impact on what's going on with the pandemic I think was very exciting for our students," said Stagnaro-Green.

Stagnaro-Green says administrators were able to modify the elective courses to help the students speed up their last year.

Nelson Nwumeh is a University of Illinois College of Medicine Rockford Class of 2020 graduate and says he feels honored to help.

"This is what we signed up for and if nothing else it's motivation to actually practice what we preach," said Nwumeh.

Despite the amount of schooling, these new doctors are entering the field during a stressful and uncertain time.

'It's going to be tough there's going to be situations you've never encountered situations that no amount of reading or in hospital time could prepare you for," said Nwumeh.

"So do I think they're ready definitely and do I think it's a difficult transition under the best of time," said Stagnaro-Green.

See original here:

The University of Illinois College of Medicine Rockford fast-tracks final year medical students - WIFR

How to Re-Stock the Modern-Day Medicine Cabinet, According to Dr. Nicole Avena – Business Wire

NEW YORK--(BUSINESS WIRE)--At a time when health and wellness are on the forefront of our minds, Nicole Avena, Ph.D. urges people to remember that positive diet and fitness choices today will yield a healthier you tomorrow. Furthermore, the products you keep on hand present an opportunity to make sure you are doing all you can to boost your immune system while maintaining an overall healthy lifestyle.

This is a good time to ask yourself if your medicine cabinet is equipped to supplement your health goals and if it is not, it might be time to rethink your strategy. What you put into your body greatly impacts how you feel, and you want to make sure that the items in your trusted medicine cabinet pack an immunity punch. Thats why its important to focus on time-tested items with a variety of benefits, says Dr. Nicole Avena.

Below, Dr. Avena offers her medicine cabinet-must haves:

While your bodys immune system does its best to fight whatever comes its way, its important to give your system a boost and arm it with the best tools available. We could all benefit from taking the time to restock our medicine cabinet with supplements and multipurpose, natural items proven by time to be some of the best help your body can get, adds Avena.

View post:

How to Re-Stock the Modern-Day Medicine Cabinet, According to Dr. Nicole Avena - Business Wire

Avoid face irritation, acne while wearing masks – Baylor College of Medicine News

The COVID-19 pandemic has brought about many changes to peoples lives, including wearing a protective face mask while out in public in some cities. Although wearing a non-medical grade face mask is an important way to keep the virus from spreading, it is possible that the mask can cause skin irritation and acne breakouts, according to a dermatology expert at Baylor College of Medicine.

Your skin barrier helps protect you in many ways, but friction, rubbing and sweat trapped underneath a mask can cause the skin barrier to break down, said Dr. Rajani Katta, a dermatologist and clinical assistant professor at Baylor. Whenever you get an impairment of the skin barrier, you may start to see irritation or irritant dermatitis. It can cause redness, marks and flaking skin. For some people, those same factors can trigger acne.

Katta offers tips on how to avoid irritating or breaking out your skin while wearing protective masks:

Find the right fabric

One of the most important things to pay attention to is the fabric that you are using, because that can make a big difference, she said.

If you are prone to acne, Katta recommends avoiding masks made of fabrics like polyester that tend to trap sweat underneath. Using a mask with an inner layer made from an absorbent material such as cotton can help absorb sweat and is less likely lead to breakouts.

For sensitive skin, avoid fabrics with a rough texture that can cause irritation. If you are making your own masks, Katta suggests using a softer fabric for the inner layer of the mask that is against the skin.

The outer layer can be a thicker weave to provide more protection from microbes, while the inside is a softer fabric, Katta said. A lot of the instructions for homemade masks say that layers may be more helpful in terms of providing protection from microbes, but that might also be a strategy to help protect your skin.

Be careful with products

If you have dry or sensitive skin, prepping your skin with moisturizer before wearing a mask may help fight irritation, Katta said. On the other hand, if you are acne prone, she recommends avoiding certain kinds of makeup or products that are thick and greasy, like foundation.

These products can get trapped under the mask and possibly cause more skin issues, Katta said.

If you choose to wear makeup or a skin care product, double check to be sure it is non-comedogenic so that it does not clog your pores.

Alternate or wash masks

It is essential to avoid reusing the same mask to stop the spread of germs, but it can also have an effect on the skin. For reusable fabric masks, Katta recommends frequently washing them in hot water after wearing them, and making several so you can rotate them.

It is important to launder masks on a regular basis since they are going to collect sweat and microbes that are sitting on your skin, Katta said. When washing masks, Katta said to avoid detergent or dryer sheets with fragrance and additives that could irritate the skin.

Read more:

Avoid face irritation, acne while wearing masks - Baylor College of Medicine News

UW Medicine says nasal swabs it bought from China are OK despite contamination to other parts of coronavirus testing kits – The Seattle Times

By

Seattle Times staff reporter

Scientists at UW Medicine have determined that tens of thousands of nasal swabs the health system imported from China were not affected by contamination discovered in other parts of its testing kits.

UW Medicine took extraordinary measures in early April to airlift some 80,000 kits for statewide use during a national shortage of testing swabs and the specimen-preserving liquid needed for diagnostic testing.

The health care system imported the testing kits after making a connection through a Seattle businesswomans relationship with a Chinese sales contact, who had a loose connection to a doctor in the countrys Hubei province who helped secure the supplies. An Amazon-chartered jet flew some $125,000 worth of testing kits from Shanghai to the U.S.

The story of the testing kits,which The Seattle Times detailed this month, illustrated the need for testing materials and the lengths and financial risks officials were willing to go to get more kits.

After tens of thousands of the kits were distributed to partners including the Washington State Department of Health and Public Health Seattle & King County, UW Medicine determined a small percentage of vials contained specimen-preserving liquid contaminated with a common bacterium. Some of the liquid had begun to change from hot pink to orange in color, a sign that its chemistry had altered.

UW Medicine recalled the testing kits after discovering the problem and last week began to test the nasal swabs included separately from the vials to ensure they were safe for use.

The nasal swabs were not affected by the contamination, spokeswoman Susan Gregg said in an email.

We have tested samples of the swabs and have not found any contamination that would preclude their use, Gregg said. We plan to use the swabs at UW Medicine with tubes of sterile saline for transport.

UW Medicine recommended that local and state agencies in receipt of the testing kits discard the vials of preserving liquid, but that it was up to their discretion to use the nasal swabs, Gregg said.

Go here to read the rest:

UW Medicine says nasal swabs it bought from China are OK despite contamination to other parts of coronavirus testing kits - The Seattle Times

April 30 – Mercer University School of Medicine to Hold Virtual Commencement this Saturday – Savannah Business Journal

April 30, 2020 - Mercer University School of Medicine will hold a virtual commencement on Saturday, May 2, at 2 p.m. At that time, a video of the ceremony will be posted on the medical schoolscommencement webpagefor viewing.

Since many of the graduates will soon depart for residency programs around the country, the School of Medicine is proceeding with its commencement on the originally scheduled date while adapting it to a virtual format due to social distancing measures being taken during the COVID-19 pandemic.

Saturdays virtual ceremony will include nearly all the same components of a traditional commencement, including a welcome from Mercer University President William D. Underwood, greetings from School of Medicine Dean Jean Sumner, M.D., and the introduction of several special guests by Mercer Provost D. Scott Davis, Ph.D.

The special guests numerous notable Georgians representing a diversity of fields such as politics, music and sports will each share words of encouragement with the School of Medicines Class of 2020, composed of native Georgians set to begin the next step in their journeys to use their talents to better the state and beyond.

The Schools founding mission is to educate physicians and health professionals to meet the primary care and health care needs of rural and medically underserved areas of Georgia.

Graduation is a very special occasion for these young people who have worked so hard and long for advanced degrees. They have studied hard, some for up to 20 years, to reach this milestone, and often their families have sacrificed to assist them. It is disappointing that they cannot experience an in-person ceremony to mark this milestone, but they have accepted this like the true professionals they have become, said Dr. Sumner. The School of Medicine is working diligently to develop a very special commencement that we hope will recognize our graduates and their families. Mercer University School of Medicine, our faculty, staff and students are very proud of them.

Each of the 178 graduates will be shown on screen as his or her name is read.

Degrees to be conferred include the Master of Family Therapy, Master of Science in Preclinical Sciences, Master of Science in Biomedical Sciences and Doctor of Medicine.

The Universitys three other commencements have been rescheduled. The School of Law ceremony will take place Aug. 7 at 1 p.m. in Hawkins Arena in Macon. The Macon ceremony will take place Aug. 8 at a time to be announced in Hawkins Arena, and the Atlanta ceremony will take place Aug. 9 at 3 p.m. in the Infinite Energy Center in Duluth.

Read the original post:

April 30 - Mercer University School of Medicine to Hold Virtual Commencement this Saturday - Savannah Business Journal

New option for treating upper tract urothelial cancer – Baylor College of Medicine News

Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments. An international team led by researchers at Baylor College of Medicine reports in the journal The Lancet Oncology that an innovative form of local chemotherapy using a mitomycin-containing reverse thermal gel offers a kidney-sparing treatment option for this rare cancer affecting 6,000 to 8,000 new patients in the United States every year.

Urothelial cancer refers to a cancer of the lining of the urinary system. While about 9 of 10 urothelial cancers arise in the bladder (lower tract), a small subset arises in the upper tract, in the lining of the kidney or the ureter, the long, thin tube that connects that kidney to the bladder, said corresponding and senior author Dr. Seth P. Lerner, professor of urology and Beth and Dave Swalm Chair in Urologic Oncology at Baylor.

To spare patients having to undergo radical kidney surgery, physicians treated the cancer with a novel formulation of mitomycin, a form of chemotherapy that urologists use to treat low-grade cancers of the bladder. Standard formulations of mitomycin are administered in a water-based solution that is washed away by the urine produced by the kidney, shortening the time the drug is in direct contact with the urothelium, which lessens the effect of the treatment. To overcome the shortcomings of standard mitomycin treatment, Lerner and his colleagues evaluated a mitomycin-containing reverse thermal gel (UGN-101, brand name Jelmyto, manufactured by UroGen Pharma).

UGN-101 is semi-solid at body temperature and becomes a viscous liquid at colder temperatures that can be injected via a catheter passed from the bladder into the renal pelvis where these tumors occur, Lerner said. The reverse thermal properties of UGN-101 allow for local administration of mitomycin as a liquid, which subsequently transforms into a semi-solid gel depot as it warms up following instillation into the urinary upper tract. Normal urine flow dissolves the gel depot, allowing tissue exposure to mitomycin over a period of 4 to 6 hours.

The researchers previously reported proof-of-concept and preliminary safety data for UGN-101 in treating 22 patients with upper tract urothelial cancer in a compassionate-use program. In the current study, Lerner and his colleagues conducted a phase 3 single-arm clinical trial to further evaluate the efficacy of the innovative reverse gel delivery of mitomycin in low-grade upper tract urothelial cancer.

Seventy-one patients received six weekly treatments with mitomycin-containing reverse thermal gel. Patients who had a complete response (complete disappearance of the tumor) were offered monthly treatments for up to 11 additional months. Efficacy of the treatment was evaluated using urine cytology (a test to look for abnormal cells in a patients urine), ureteroscopy (an examination of the upper urinary tract) and biopsy (if warranted) three months following the initiation of therapy.

The treatment was beneficial. Following the initial six weekly treatments, 59 percent of the patients had no residual tumors, including patients with cancer deemed unresectable at diagnosis, who represented 48 percent of the overall treatment population. There were side effects, including urinary tract infection, hematuria (blood in urine), flank pain and nausea, but the severity and frequency were as expected from patients who are undergoing similar interventions. The study will continue to monitor the durability of the initial response out to 12 months.

The treatment has been recently approved by the U.S. Food and Drug Administration and became the first and only approved non-surgical treatment available for patients with low-grade upper tract urothelial cancer.

The clear benefit is that patients get to keep their kidney. For people who have one kidney, this option also removes the need for dialysis, Lerner said. Other potential beneficiaries would be patients for whom, because of other conditions, it would be too risky to perform an operation to remove the kidney. Now they have an option for treatment.

Other contributors to this work include Nir Kleinmann, Surena F. Matin, Phillip M. Pierorazio, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott Hubosky, Marcelino Rivera, Michael ODonnell, Marcus Quek, Jay D. Raman, John J. Knoedler, Douglas Scherr, Joshua Stern, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B. Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R. Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Mehrad Adibi, Mahul B. Amin, Elyse Seltzer, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim and Mark Schoenberg.

For a complete list of the contributors affiliations and declaration of interests visit the publication. This trial was supported with funding from UroGen Pharma.

See the article here:

New option for treating upper tract urothelial cancer - Baylor College of Medicine News

Doctor on frontline issues warning for COVID-19 treatment: ‘This medicine … will surely kill them’ – TheBlaze

Dr. Tom Yadegar, a specialist in critical care medicine who has been treating some of the most extreme cases of the coronavirus, joined Glenn Beck on the radio program Tuesday to share some important information with the public and doctors around the world about treating COVID-19.

As the intensive care unit director at Providence Cedars-Sinai Tarzana Medical Center in California, Yadegar and has been treating patients with COVID-19 for about seven weeks and has not lost a single patient. He was recently asked to command four more regional hospitals because he and his team are performing well above other hospitals in the Los Angeles area.

Yadegar created a protocol to determine which patients with COVID-19 also have what's called "cytokine storm syndrome" -- a process by which the body's immune system rapidly releases too many cytokines into the blood.

"The immune system kind of goes awry. It doesn't act normally. The immune system gets super ramped up, and instead of attacking the virus, it attacks the patient's own vital organs," Yadegar explained. "It's actually [the patient's] own immune system that's causing the problem, not necessarily the virus.

"Don't get me wrong. This is a deadly virus. Just like the influenza virus, it can definitely cause pneumonia. It can definitely cause respiratory failure. If the patient has emphysema or heart failure, it can definitely exacerbate those," he added. "But this [coronavirus] was doing something unique. This was doing something that I really hadn't seen much in my 20 years, where it was activating the immune system. And then the immune system was causing all the destruction in the lungs."

Yadegar noted that, while a virus triggering an autoimmune disease is not necessarily an "unknown thing," the COVID-19 virus "does it at an extraordinary pace" and to a significant number of patients. He stressed the importance of recognizing that not every patient with COVID-19 will develop an autoimmune disease and that every case must be treated individually.

"One thing that I can't stress any harder to you and your listeners. There isn't necessarily one test, and there isn't one particular treatment plan. Every patient has their own kind of individual disease," he said. "You can't treat everyone with the same treatments. There isn't a one-size-fits-all for this disease. You have to do your due diligence. You have to look at the patient in front of you and then, you know, come up with a treatment for the disease that that patient is manifesting. You can't just go through the ICU, and start handing out these medicines. If you give this medicine to someone who doesn't need it, you will surely kill them."

Watch the video below for more details:

In response to the COVID-19 crisis, BlazeTV is offering our BIGGEST discount ever! Get $30 off your subscription when you use promo code GLENN. Claim your special offer at https://get.blazetv.com/glenn/.

Want more from Glenn Beck?

To enjoy more of Glenn's masterful storytelling, thought-provoking analysis and uncanny ability to make sense of the chaos, subscribe to BlazeTV the largest multi-platform network of voices who love America, defend the Constitution and live the American dream.

View post:

Doctor on frontline issues warning for COVID-19 treatment: 'This medicine ... will surely kill them' - TheBlaze

Treating low testosterone levels – Harvard Health

Testosterone is the hormone that gives men their manliness. Produced by the testicles, it is responsible for male characteristics like a deep voice, muscular build, and facial hair. Testosterone also fosters the production of red blood cells, boosts mood, keeps bones strong, and aids thinking ability. Lack of testosterone, often nicknamed, low-t, can cause unwanted symptoms.

Testosterone levels peak by early adulthood and drop as you ageabout 1% to 2% a year beginning in the 40s. As men reach their 50s and beyond, this may lead to signs and symptoms, such as impotence or changes in sexual desire, depression or anxiety, reduced muscle mass, less energy, weight gain, anemia, and hot flashes. While falling testosterone levels are a normal part of aging, certain conditions can hasten the decline. Low t risk factors include:

Millions of men use testosterone replacement therapy to restore low levels and feel more alert, energetic, mentally sharp, and sexually functional. But it's not that simple. A man's general health also affects his testosterone levels. For instance, being overweight, having diabetes or thyroid problems, and taking certain medications, such as glucocorticoids and other steroids, can affect levels. Therefore, simply having low-t levels does not always call for taking extra testosterone.

Doctors diagnose low testosterone based on a physical exam, a review of symptoms, and the results of multiple blood tests since levels can fluctuate daily.

If your doctor diagnoses low testosterone, other tests may be considered before therapy. For example, low-t can speed bone loss, so your doctor may recommend a bone density test to see whether you also need treatment for osteoporosis.

Prostate cancer is another concern, as testosterone can fuel its growth. As a result, the Endocrine Society recommends against testosterone supplementation for men in certain situations, including those who:

Other circumstances in which testosterone supplementation is not recommended include:

In most cases, men need to have both low levels of testosterone in their blood and several symptoms of low testosterone to go on therapy.

It is possible to have low levels and not experience symptoms. But if you do not have any key symptoms, especially fatigue and sexual dysfunction, which are the most common, it is not recommended you go on the therapy given the uncertainty about long-term safety.

Even if your levels are low and you have symptoms, low-t therapy is not always the first course of action. If your doctor can identify the source for declining levelsfor instance, weight gain or a particular medicationhe or she may first address that problem.

If you and your doctor think testosterone replacement therapy is right for you, there are a variety of delivery methods to consider, as found in the Harvard Special Health Report Men's Health: Fifty and Forward.

Most men feel improvement in symptoms within four to six weeks of taking testosterone replacement therapy, although changes like increases in muscle mass may take from three to six months.

By Matthew SolanExecutive Editor, Harvard Men's Health Watch

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

See the original post:
Treating low testosterone levels - Harvard Health

Low T Treatment in Texas | SynergenX | Licensed …

Low T, which is a lower-than-normal level of the male hormone testosterone, can affect men in a variety of ways. It can also have a number of potential causes, including:

Really, age is the most common reason for Low T. Thats because most men begin to experience a decline in testosterone, albeit a gradual one, after age 30. Generally, testosterone levels peak during adolescence or early adulthood, and its pretty much all downhill from there. The older you become, the lower your T levels, and its faster for some men than for others.

Whatever the reason or reasons behind it, Low T can cause or contribute to a number of conditions that disrupt Mens lives and can affect their productivity, relationships and sense of worth or self-identity. These include:

At SynergenX, we treat Low-T with hormone replacement therapyand we do it differently. We tailor the treatment and dose to each mans individual needsas informed by lab tests. We also differ from the typical hormone treatment protocol by testing continually and varying the dose as your T levels rise and fall, because they do. By continually, actively monitoring patients and adjusting treatment, we minimize the risksand help most men achieve a marked, positive change and a reinvigorated life and sense of self.

SynergenX also offers a tailored, effective weight management program to help men lose weight, keep it off for optimal health, and maximize the effects of their Low T treatment to both feel and look great. And speaking of looking your best, SynergenX offers aesthetic services designed to bring your appearance into harmony with how great you feel on the inside.

For more information about the conditions and symptoms SynergenX can help with, or to schedule an appointment for a FREE Low T test in Texas, in McKinney, Texas, North Park, Woodlands, Kingwood, Vintage Park, Katy, Galleria, Cypress, Burr Ridge, TX, Sonterra San Antonio, Dallas, Houston, Chicago, IL, or Northwest San Antonio, call 877-915-2554 or use our easy online form.

Go here to see the original:
Low T Treatment in Texas | SynergenX | Licensed ...

Low T Symptoms Quiz: Do I Have Low Testosterone Quiz …

As we age, hormone production begins to decrease. For men, this means producing lower levels of testosterone which, if left untreated, can cause an array of unpleasant symptoms. Need to know if youre experiencing symptoms of Low T? Take this quiz below and find out.

Low testosterone can manifest itself in a number of ways. Some of the most common symptoms experienced are weight gain, weakness, fatigue, loss of libido, mood disturbances, and hair loss.

Testosterone has a widespread impact on the way the body works and affects nearly every organ system. T plays a key role in metabolism, by affecting how the body uses its caloric intake and encouraging muscle protein synthesis. Excess abdominal fat can decrease the bodys levels of testosterone and boost estrogen production in males.

The most common reason for lowered T production is simply aging. Research has shown that testosterone levels in aging males fall 1-2% each year after age thirty.

Scientists have also found a link between low T and chemical imbalances in the brain, which may be why men with low T frequently report symptoms such as low libido, fatigue, and mood disturbances.

In recent years two different studies one done by researchers at Saint Louis University and the other by the Kobe University Graduate School of Medicine in Japan found that testosterone replacement therapy was an effective treatment for mild depression.

Men who have low T frequently report muscle weakness this is sometimes due to a decrease in muscle mass caused by low T levels.

Evidence has shown that both high and low levels of T can cause mood disturbances and emotional side effects.

Low libido is a common side effect of low T and is one of the main reasons men with low T pursue hormone replacement therapy,

As testosterone levels decrease men usually begin to see an increase in weight gain. Stomach fat, in particular, can increase estrogen levels in men, which can make T levels drop even further.

Often, low T goes hand-in-hand with low bone density (osteoporosis). The Endocrine Society lists TRT as an effective treatment option for men with low bone density and hypogonadism.

Testosterone plays a vital role in muscle building and maintenance. When T levels drop, men frequently report a decrease in muscle mass and strength.

Testosterone levels spiking during puberty leads to hair growth and other primary and secondary sex traits in young men. But as those levels diminish in older men, testosterone loss can often bring about thinner hair and male pattern baldness.

While low T isnt a direct cause of ED in aging men, its frequently seen as a contributor to sexual dysfunction because it decreases libido and can cause a lack of enjoyment of intimacy.

Testicular shrinkage and a decrease in sperm output is a common symptom of men with hypogonadism.

Though typically thought of as a menopause symptom, andropause can cause this uncomfortable side effect as well.

To find out if you have Low T, click the button below to take the quiz.

Link:
Low T Symptoms Quiz: Do I Have Low Testosterone Quiz ...

Hypogonadism – Wikipedia

"Low T" redirects here. It is not to be confused with LOWT or T Low.

Endocrine disease

Hypogonadism means diminished functional activity of the gonadsthe testes or the ovariesthat may result in diminished production of sex hormones.

Low androgen (e.g., testosterone) levels are referred to as hypoandrogenism and low estrogen (e.g., estradiol) as hypoestrogenism. These are responsible for the observed signs and symptoms. Hypogonadism can decrease other hormones secreted by the gonads including progesterone, DHEA, anti-Mllerian hormone, activin, and inhibin. Sperm development (spermatogenesis) and release of the egg from the ovaries (ovulation) may be impaired by hypogonadism, which, depending on the degree of severity, may result in partial or complete difficulty or inability to have children.

In January 2020, the American College of Physicians issued clinical guidelines for testosterone treatment in adult men with age-related low levels of testosterone. The guidelines are supported by the American Academy of Family Physicians. The guidelines include patient discussions regarding testosterone treatment for sexual dysfunction; annual patient evaluation regarding possible notable improvement and, if none, to discontinue testosterone treatment; physicians should consider intramuscular treatments, rather than transdermal treatments, due to costs and since the effectiveness and harm of either method is similar; and, testosterone treatment for reasons other than possible improvement of sexual dysfunction may not be recommended.[1][2]

Deficiency of sex hormones can result in defective primary or secondary sexual development, or withdrawal effects (e.g., premature menopause) in adults. Defective egg or sperm development results in infertility. The term hypogonadism usually means permanent rather than transient or reversible defects, and usually implies deficiency of reproductive hormones, with or without fertility defects. The term is less commonly used for infertility without hormone deficiency. There are many possible types of hypogonadism and several ways to categorize them. Hypogonadism is also categorized by endocrinologists by the level of the reproductive system that is defective. Physicians measure gonadotropins (LH and FSH) to distinguish primary from secondary hypogonadism. In primary hypogonadism the LH and/or FSH are usually elevated, meaning the problem is in the testicles, whereas in secondary hypogonadism, both are normal or low, suggesting the problem is in the brain.

Hypogonadism can involve just hormone production or just fertility, but most commonly involves both.

Women with hypogonadism do not begin menstruating and it may affect their height and breast development. Onset in women after puberty causes cessation of menstruation, lowered libido, loss of body hair, and hot flashes. In men it causes impaired muscle and body hair development, gynecomastia, decreased height, erectile dysfunction, and sexual difficulties. If hypogonadism is caused by a disorder of the central nervous system (e.g., a brain tumor), then this is known as central hypogonadism. Signs and symptoms of central hypogonadism may involve headaches, impaired vision, double vision, milky discharge from the breast, and symptoms caused by other hormone problems.[5]

The symptoms of hypogonadotrophic hypogonadism, a subtype of hypogonadism, include late, incomplete or lack of development at puberty, and sometimes short stature or the inability to smell; in females, a lack of breasts and menstrual periods, and in males a lack of sexual development, e.g., facial hair, penis and testes enlargement, deepening voice.

Low testosterone can be identified through a simple blood test performed by a laboratory, ordered by a health care provider. Blood for the test must be taken in the morning hours, when levels are highest, as levels can drop by as much as 13% during the day and all normal reference ranges are based on morning levels.[6] However, low testosterone in the absence of any symptoms does not clearly need to be treated.

Normal total testosterone levels depend on the man's age but generally range from 240950ng/dL (nanograms per deciliter) or 8.3-32.9 nmol/L (nanomoles per liter).[7] According to American Urological Association, the diagnosis of low testosterone can be supported when the total testosterone level is below 300ng/dl.[8] Some men with normal total testosterone have low free or bioavailable testosterone levels which could still account for their symptoms. Men with low serum testosterone levels should have other hormones checked, particularly luteinizing hormone to help determine why their testosterone levels are low and help choose the most appropriate treatment (most notably, testosterone is usually not appropriate for secondary or tertiary forms of male hypogonadism, in which the LH levels are usually reduced).

Treatment is often prescribed for total testosterone levels below 230ng/dL with symptoms.[9] If the serum total testosterone level is between 230 and 350ng/dL, free or bioavailable testosterone should be checked as they are frequently low when the total is marginal.

The standard range given is based on widely varying ages and, given that testosterone levels naturally decrease as humans age, age-group specific averages should be taken into consideration when discussing treatment between doctor and patient.[10] In men, testosterone falls approximately 1 to 3 percent each year.[11]

A position statement by the Endocrine Society expressed dissatisfaction with most assays for total, free, and bioavailable testosterone.[12] In particular, research has questioned the validity of commonly administered assays of free testosterone by radioimmunoassay.[12] The free androgen index, essentially a calculation based on total testosterone and sex hormone-binding globulin levels, has been found to be the worst predictor of free testosterone levels and should not be used.[13] Measurement by equilibrium dialysis or mass spectroscopy is generally required for accurate results, particularly for free testosterone which is normally present in very small concentrations.

Testing serum LH and FSH levels are often used to assess hypogonadism in women, particularly when menopause is believed to be happening. These levels change during a woman's normal menstrual cycle, so the history of having ceased menstruation coupled with high levels aids the diagnosis of being menopausal. Commonly, the post-menopausal woman is not called hypogonadal if she is of typical menopausal age. Contrast with a young woman or teen, who would have hypogonadism rather than menopause. This is because hypogonadism is an abnormality, whereas menopause is a normal change in hormone levels. In any case, the LH and FSH levels will rise in cases of primary hypogonadism or menopause, while they will be low in women with secondary or tertiary hypogonadism.

Hypogonadism is often discovered during evaluation of delayed puberty, but ordinary delay, which eventually results in normal pubertal development, wherein reproductive function is termed constitutional delay. It may be discovered during an infertility evaluation in either men or women.

Screening males who do not have symptoms for hypogonadism is not recommended as of 2018.[14]

Male primary or hypergonadotropic hypogonadism is often treated with testosterone replacement therapy if they are not trying to conceive.[9] Adverse effects of testosterone replacement therapy include increased cardiovascular events (including strokes and heart attacks) and death.[15] The Food and Drug Administration (FDA) stated in 2015 that neither the benefits nor the safety of testosterone have been established for low testosterone levels due to aging.[16][17] The FDA has required that testosterone pharmaceutical labels include warning information about the possibility of an increased risk of heart attacks and stroke.[16][17]

While historically, men with prostate cancer risk were warned against testosterone therapy, that has shown to be a myth.[18]

Other side effects can include an elevation of the hematocrit to levels that require blood withdrawal (phlebotomy) to prevent complications from excessively thick blood. Gynecomastia (growth of breasts in men) sometimes occurs. Finally, some physicians worry that obstructive sleep apnea may worsen with testosterone therapy, and should be monitored.[19]

Another treatment for hypogonadism is human chorionic gonadotropin (hCG).[20] This stimulates the LH receptor, thereby promoting testosterone synthesis. This will not be effective in men who simply cannot make testosterone anymore (primary hypogonadism) and the failure of hCG therapy is further support for the existence of true testicular failure in a patient. It is particularly indicated in men with hypogonadism who wish to retain their fertility, as it does not suppress spermatogenesis like testosterone replacement therapy does.

For both men and women, an alternative to testosterone replacement is low-dose clomifene treatment, which can stimulate the body to naturally increase hormone levels while avoiding infertility and other side effects that can result from direct hormone replacement therapy.[21] Clomifene blocks estrogen from binding to some estrogen receptors in the hypothalamus, thereby causing an increased release of gonadotropin-releasing hormone and subsequently LH from the pituitary. Clomifene is a selective estrogen receptor modulator (SERM). Generally, clomifene does not have adverse effects at the doses used for this purpose. Clomifene at much higher doses is used to induce ovulation and has significant adverse effects in such a setting.

Here is the original post:
Hypogonadism - Wikipedia

Does Insurance Cover Low T Treatment – Mantality Health

The physicians at Mantality accept insurance for the treatment of testosterone deficiency, or Low T, in order to make it the most affordable option for any man seeking treatment.

According to Mantality founder Kevin J. Meuret,my desire was to help get this type of care within the reach of any man who needed treatment. Many patients who could benefit from treatment dont seek it out because of the fear of cost. We have eliminated that concern by developing a program that is covered by insurance along with Board Certified physicians guiding care.

Mantality is staffed with Board Certified medical physicians, nurse practitioners, and nurses specializing in low testosterone treatment.

Putting care within reachof every man who needs treatment is at the heart of this clinic. Testosterone treatment used to be considered elective or optional. Today we know it is essential. Men suffering with Low T are no different than men suffering with diabetes. A medical condition that is treatable needs proper diagnosis, appropriate medication, and monitoring by specialists. This is exactly what we provide.

We believe men should have access to care, and our accepting insurance gives more people that convenience.

The treatments offered by the physicians at Mantalityare customized to fit individual testosterone needs with prescription medications that can only be prescribed by licensed practitioners. The treatment is simple, covered by insurance carriers, and can be available for less than $100 a month!

We acceptallmajor insurance providers so, if you dont see yours listed, give us a call.

Read the original post:
Does Insurance Cover Low T Treatment - Mantality Health

Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly -…

The Low T Therapy Market (2020) research report explores the market in terms of Revenu, Emerging Market Trends and Driver includes up to date analysis and forecasts for various market segments, major players, and all geographical regions till 2027.

The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report. The report will account for Covid19 as a key market contributor.

The top players covered in Low T Therapy Market are: AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals

Download Sample PDF PagesClick Here!

This report sample includes: Brief Introduction to the research report, Table of Contents (Scope covered as a part of the study), Top players in the market, Research framework (presentation), Research methodology adopted by Worldwide Market Reports

Low T Therapy Market Outlook:

Global Low T Therapy market report provides exclusive coverage that has been provided for market drivers and challenges & opportunities for a country-level market in the respective regional segments. The report comprises a competitive analysis of the key players functioning in the market and covers in-depth data related to the competitive landscape of the market and the recent strategies & products that will assist or affect the market in the coming years.

Market Drivers and the Risks Associated with the Low T Therapy Market:

The international Low T Therapy market has been characterized by several primary factors, with each factor tends of playing a crucial role in the boom of the market. The growth in the products has doubled with the smoother availability of the customer base that has been helping the company of flourishing globally. On the other hand, the presence of a dynamic supply chain has helped the company to grow exponentially. Therefore, regarding the increase in the opportunities of the market Low T Therapy faces severe complaints from all the aspects.

Enumerating some of the fundamental parameters encompassed in the report:

Major Geographical Regions and Market of the Low T Therapy Market:

When a better look taken at the areas, the market has concentrated, and the file interior the important makes a strong point of Europe, Middle East & Africa, Asia Pacific, Latin America, and North America. These areas have studied regarding the hooked-up traits and the diverse possibilities in addition to the outlook that allows inside the benefitting of the market ultimately.

Buy This Complete Business Report: Access Insightful Study With Over 100+ Pages, List of Tables and Figures, Profiling 10+ Companies Click Here!

Low T Therapy Market Report Covers Following Questions:

Customization Service of the Report: Place Query: Click Here!

Worldwide Market Reports provides customization of reports as per your request. This report can be personalized to meet your requirements. Get in touch with our research team, who will make sure you get a report that suits your necessities.

Continued here:
Peek on Low T Therapy Market Future, Extensive Studies and Prediction of Top Manufacturers Condition: AbbVie, Endo International, Eli Lilly -...

BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho’s Phase 1 HIF-PH Inhibitor to Treat Aging – BioSpace

BioAges proprietary platform of human aging data demonstrates that the Hypoxia-inducible factor (HIF) pathway is linked to healthspan and lifespan

RICHMOND, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- BioAge Labs, Inc., a biotechnology company developing medicines to treat aging and age-related diseases, today announced that it has entered into an exclusive worldwide license agreement with Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo, President: Shigeru Uehara] (Taisho) to develop and commercialize Taisho's clinical-stage Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, BGE-117 (named TS-143 by Taisho), to ameliorate multiple diseases of aging.

This is a significant milestone for BioAge that enables us to initiate our first clinical trial of BGE-117 to evaluate the impact of HIF activation on several measures of aging in elderly patients. Our proprietary human data platform shows that HIF signaling is a key longevity pathway that drives regeneration, healing and resilience, said Kristen Fortney, PhD, BioAges Chief Executive Officer. BioAges AI-driven platform is built on longitudinal human aging samples with multi-omics phenotyping and has revealed multiple pathways and mechanisms where we can intervene to positively impact human healthspan and lifespan. BGE-117 is the first of several promising therapies that we plan to bring forward to treat diseases of aging.

Under the terms of the agreement, BioAge will make an upfront payment to Taisho, who is entitled to receive development and commercial milestone payments plus royalties based on annual net sales. BioAge will be responsible for all development, manufacturing and commercialization of BGE-117 worldwide while Taisho has an option right for co-commercialization in Japan and several countries in Southeast Asia.

The Hypoxia-inducible factor (HIF) pathway is linked to healthspan and lifespan in BioAges proprietary human aging data. Pathway activation levels are significantly associated with longevity and multiple functional measures. The Company believes that BGE-117 can potentially treat multiple diseases of aging through the activation of HIF-1 target genes that are involved in numerous biological processes including tissue regeneration, erythropoiesis, glycolysis, glucose uptake, vascular remodeling and angiogenesis. Inhibition of HIF-PH increases HIF pathway activation and has the potential to increase resilience, repair and regeneration across multiple body systems.

BGE-117 is a potent, orally administered small molecule inhibitor of HIF-PH demonstrating early clinical activity and safety in a Phase 1 study in healthy volunteers and a Phase 1 study in non-dialysis and hemodialysis patients with chronic kidney disease.1 HIF-PH inhibitors are an emerging class of compounds that have been demonstrated to be safe and well-tolerated in over 20,000 subjects in clinical trials.

About the BioAge Platform The BioAge platform identifies key drug targets that impact aging. The Companys proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan and disease outcomes. BioAge has built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. BioAges pipeline of development candidates targeting these key pathways has the potential to address the significant unmet medical needs of an aging population.

About BioAgeBioAge is a biotechnology company developing proprietary drugs to treat aging and aging-related diseases. Since its founding in 2015, the Company has raised $37 million in venture capital funding from Andreessen Horowitz, Khosla Ventures, Felicis Ventures and others to back its AI-driven approach to map the molecular pathways that impact human longevity. BioAges mission is to develop a pipeline of therapeutic assets that increase healthspan and lifespan.

Reference1 Am J Nephrol. 2018;48(3):157-164

Source: BioAge Labs, Inc.

Contact Information:

BioAge | peng@bioagelabs.com

Media | denise@redhousecomms.com

Originally posted here:
BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho's Phase 1 HIF-PH Inhibitor to Treat Aging - BioSpace

Al Southwick: Thought of living to 150 leaves me with mixed emotions – Worcester Telegram

Since my 80th birthday 20 years ago, I have been inundated by a flood of information about the elderly and their needs. Old age or at least anti-aging has become a cottage industry online, on television, in magazines, wherever. I thought I was pretty much inured to all that.

But now there is something new to think about. The Wall Street Journal recently published a piece on living to be 150. Rather, it published two pieces one by an epidemiologist predicting that it will happen in the next 75 years, and the second by a biologist who thinks that it wont. The two have wagered $300 apiece on the outcome, the payoff coming 75 years from now.

The possibility of living to 150 leaves me with mixed emotions, to put it mildly. I will hit 100 in a few weeks, a milestone long thought to be impressive. According to the New England Centenarian Study at Boston University, there are an estimated 343,000 folks over 100 living on the globe today, 80,000 in the United States, 800 in New England. The U.S. figures include 32,000 who are over 105. A United Nations study predicts there will be 3.2 million centenarians in 2050. Average life expectancy has jumped from 48 to 77 in the last century.

The New England Centenarian Study has been compiling statistics on old folks since 1995. It has three categories centenarians, semi-supercentarians (ages 105-109), and supercentarians (110 and up}. It now accepts only candidates who are 103 or over, so Im going to have to wait for a while. Among other findings, it has concluded that longevity is largely genetic. That figures. My older sister checked out at 103, most of my other siblings in their 90s or late 80s.

Ill admit that over the past 20 years or so I sometimes wondered if I would reach the century mark. I regarded it as a sort of goal. Now that Im on the threshold, I feel reasonably content and satisfied. I dont seem to have a goal say 105 in the same way that I used to. Why not? If I looked forward to reaching 90 when I hit 80 and to 100 when I reached 90, why would I not now anticipate 105 as my next goal?

The answer is complicated and involves subtle psychological and emotional factors. The fact is that I want to be realistic. The five years since my 95th birthday have been more difficult than the preceding five. Anyone who approaches the century mark has experienced various difficulties, physical and emotional. These do not diminish with passing of time. Anything but.

I say this as someone who has enjoyed extraordinary luck throughout my life. I got through four years of war in the Navy without a scratch. Ive had two remarkably fulfilling marriages and a satisfying career. Now, in my declining years, I have a cluster of relatives children, nieces, nephews and friends who do much to make my life a pleasing and productive experience. I cant praise them enough. The coronavirus has limited my visitor list, but I still communicate by phone and Skype with those I care about. Life is still worth living, despite the various handicaps of old age. I still enjoy it.

Tremendous advances have been made in human health since I was born. A baby girl born this week can expect to reach 80, a baby boy a bit less. On the average. Thats a huge increase over such expectations in 1920. Many diseases, once killers, have been eliminated, and the quality of life for us seniors has improved greatly, but there are limits. The agng process continues its relentless way. The centenarian study folks find that the upper limit of longevity may be 115 or thereabouts. Thats if everything everything goes right for a century or more.

I sometimes have to remind my caregivers that a 1920 model human or automotive needs constant maintenance. Its something we oldies just have to live with.

Now lets get on with it.

Originally posted here:
Al Southwick: Thought of living to 150 leaves me with mixed emotions - Worcester Telegram

The evolution of Cristiano Ronaldo – beIN SPORTS New Zealand

Ronaldos longevity and consistency over the past 17 seasons is staggering, with 725 goals in 1000 appearances for club and country.

To celebrate a remarkable career to date, beIN 1 will be dedicated to Cristiano tonight from 7pm (AEST), with his best goals and highlights, plus two match replays of the Portuguese star at his devastating best.

Like any opponent, Ronaldo has bamboozled father time, showing no signs of slowing down at 35 fuelling speculation that he could be more machine, than man.

Perhaps the secret to Ronaldos super-human longevity can be found in his evolution into four distinct forms throughout his career.

Wearing Manchester Uniteds iconic number seven jersey comes with a heavy weight of expectations, which a teenage Cristiano seemed to carry comfortably on his strapping young shoulders.

In the six seasons which followed, Ronaldo overwhelmed defences with blistering power and pace, plus a free-kick which defied physics take this sensational effort against Portsmouth in 2008.

Ronaldos flashy tricks caught the ire of Englands no-frills defenders, but theres no denying their effectiveness as Ronaldo helped United to three league titles and one UEFA Champions League triumph in his six seasons at Old Trafford.

Strengths: Pace, Power, Free-kicks, quick feet and tricks.

Weaknesses: Did not score as many goals as other stages of his career (noted he was playing on the wing)

Real Madrid made Cristiano Ronaldo the worlds most expensive footballer in 2009, which marked the second stage in his evolution.

Cristiano Ronaldo transformed from skilful trickster at Old Trafford, to ruthless goal machine at the Bernabeu, able to shrug some of his defensive responsibilities to focus solely on the attacking third.

Ronaldo added clinical finishing to his pace with devastating effect, scoring 201 goals in 199 appearances in his first four seasons, before entering the third stage of his evolution.

Strengths: Added more goals to his repertoire, significantly improved aerial ability.

Weaknesses: Lean spell of silverware two trophies from 2009-2013.

As youthful exuberance began to fade, Ronaldo fine-tuned his efficiency and focussed solely on scoring goals.

This narrowfocussed payed off as Ronaldo lead Los Blancos to 12 trophies in six seasons, including four UEFA Champions League triumphs.

On the international stage, CR7 helped guide Portugal to UEFA Euro glory in 2016, despite sitting out the final with an injury.

Strengths: Ronaldos peak output in goals and trophies.

Weaknesses: Lost a yard of pace, and his mojo with free-kicks.

While he hasnt replicated some of his stats at Real Madrid, Ronaldo

A slow debut season by Ronaldos lofty standards (which included 21 league goals) had his critics revelling, but they were silenced the following year.

The 35 year-old kicked off the 2019-2020 campaign with 21 goals in his first 22 league games, leaving Juventus at the top of the table before the spread of coronavirus brought the season to a halt.

Strengths: Able to change clubs and leagues and dominate at 35. Improved second season suggests he might have found a way to reverse ageing.

Weaknesses: Fewer goals and less productive than his time at Real Madrid.

With the league set to resume next month, we will see if Ronaldo has conjured up another evolution while stuck in isolation.

Read the original here:
The evolution of Cristiano Ronaldo - beIN SPORTS New Zealand

In appreciation of Shirley Knight, an acting model for others – Brownwood Bulletin

Luminous is an overused word in theater criticism, but the word is aptly applied to Shirley Knight, the Tony- and Emmy-winning actress who died at age 83 on April 22 in San Marcos.

Knights daughter, Kaitlin Hopkins, founded the musical theater program at Texas State University. Although she maintained a residence in Los Angeles, Knight was a presence on the campus. She died of natural causes at Hopkins home.

A product of the Actors Studio heyday, she is linked to those method stars who may have burned brighter but probably not as consistently. There was never a part, small or star, she didn't illuminate from the inside out.

After receiving an Oscar nomination for her performance in "The Dark at the Top of the Stairs," in which she played a teenager while in her mid-20s, Knight was cast as Heavenly Finley in the 1962 film version of Tennessee Williams' "Sweet Bird of Youth," directed by Richard Brooks. Her beauty had a celestial quality that might have seemed to earn her the part. But there was more to the actress than Hollywood glamour. There were contradictions worthy of a Williams heroine. Her Heavenly combined porcelain fragility with bitter strength. The movie belonged to Geraldine Page and Paul Newman, but Knight's Heavenly clarified the drama's tragic stakes.

In his book "A Method to Their Madness: The History of the Actors Studio," Foster Hirsch captured the vital paradox that was Knight's presence: "Blonde, with dainty features and a translucent complexion, she might have become the conventional ingenue, playing a string of decorative roles. But anger churned beneath that pretty facade, and a sour expression a stingy smile tinged with irony promised thunder."

RELATED: We Love This So Much: A Sondheim YouTube spiral

She was committed to the work of acting, to uncovering the grit of her characters, to revealing the sand caught in the gears of the human machinery. She played Irina on Broadway in Anton Chekhov's "The Three Sisters" alongside Kim Stanley and Page in the Actors Studio production directed by Lee Strasberg, passing up the chance to be the Ophelia opposite Richard Burton's Hamlet. Her loyalty was to the community that had inspired her.

Knight, who won a Tony in 1976 for her performance in Robert Patrick's "Kennedy's Children," was a throwback to an era when acting was upheld as a rigorous discipline of craft and soul. Her career had longevity because it was predicated not on great looks but on her searching humanity.

Age, in addition to adding to her trove of Emmys (including one for HBO docudrama "Indictment: The McMartin Trial"), opened up possibilities. Twice I saw her onstage in her later years, once in Horton Foote's "The Young Man From Atlanta," in which she was nominated for a Tony for a performance so suffused with detailed life that it was astonishing such a feat of naturalism could be pulled off with so little fuss. She understood the denial of the grieving mother she played down to the brand of hairspray stiffening her coiffure. It was a performance that transformed abstract psychology into unadulterated behavior.

Almost as impressive was the way Knight, working discreetly off-Broadway in Deborah Grimberg's largely forgettable "Cycling Past the Matterhorn," endowed a playwriting doddle with intricate layers of felt experience. When I reviewed the play for the Village Voice in 2005, I commented on Knight's gift for never revealing "more than what's needed, though always more than you'd expect."

RELATED: Quiz: Test your Rene Zellweger knowledge

In eulogizing Knight, I can't help thinking of her eulogy for Kim Stanley. I have a copy of the email that was read at the Actors Studio in New York in October 2001, when the city was still reeling from the 9/11 terrorist attacks. During the morning of the memorial service, New York was awash in the fresh fear of an anthrax scare. I remember wondering if I should take the subway or walk the two miles uptown. I arrived on time via subway and was uplifted by Knight's words, which communicated the values to which she held fast throughout her magnificently modest career:

I first met Kim Stanley in 1964. I was chosen by Lee Strasberg to play Irina in the Actors Studio production of Chekhov's "The Three Sisters." Imagine my excitement to discover that I was to star (in my Broadway debut) with Kim Stanley and Geraldine Page as my sisters. It would be impossible to relate how important Kim was to me in my development as an actor. I had seen her in the play about Freud and thought she gave the most extraordinary performance. One night at the beginning of the run of "The Three Sisters," Kim received applause on her exit. She came off stage muttering, "Well, that will never happen again." After the performance I asked what she meant as I assumed all applause was a good thing. She said, "Honey, if they can put their hands together, they aren't feeling (crap)." It was a revelation to me that the object as an artist was to make the audience feel and to enlighten them and that applause in the middle of a dramatic play was stopping the journey. She was always kind and loving to me as well. Another night during the run I picked up a piece of broken glass from the floor where I knew she would be kneeling. She clasped my hand and it began to bleed. She did not for a moment come out of the play but simply and lovingly placed her handkerchief on the wound. She also took me to the hospital after for stitches. Every time I look at my right palm, I am reminded of Kim. Not that I need a wound to remind me I have the memory in my mind and heart of possibly the greatest American actress in the 20th century. With love, Shirley Knight.

Knight's performances on stage and screen have etched in our memories and hearts the example of an actor who unfailingly honored her art.

American-Statesman staff writer Michael Barnes contributed to this report.

Here is the original post:
In appreciation of Shirley Knight, an acting model for others - Brownwood Bulletin

The four worlds of the social-ecological state – Social Europe

The coronavirus crisis highlights the need to update the European welfare state to a social-ecological state, able to socialise 21st-century ecological risks.

Exactly 30 years ago, the Danish sociologist Gsta Esping-Andersen proposed, in line with Richard Titmuss founding work, a new approach to the welfare state. According to him, this institution, born in Europe in the 1880s, was based on a common principle yet with differentiated regimes.

The common principle, identified by Esping-Andersen after Karl Polanyi, was that of de-commodificationthe protection of labour from market logic by means of social policy, to aim for an ethically superior value of human wellbeing. With social protection, the idea that labour was not a commodity gradually gained ground.

This guiding principle became embodied throughout the world in distinct institutional logics, which gave it more or less strength. The Esping-Andersen typology, which has become classic, was, as with Titmuss, a tripartite one, which contrasted the corporatist (as in Germany), social democratic (as in Sweden) and liberal (as in the United States) modelseach characterised by a particular purpose, funding method and governance. At the end of the 20th century, Esping-Andersen therefore perceived three worlds of what he called welfare capitalism.

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

At the same time, in the early 1990s, the Organisation for Economic Co-operation and Development undertook a long-term work to measure the impact of structural rigiditiesat their forefront the social protections which had strongly developed in Europe and beyondon labour-market performance, assessed using unemployment and growth rates. The perspective of these studies was radically opposed to that of Esping-Andersen on two counts: work was relegated to its economic utility and convergence towards a single social modela model considered almost exclusively from the angle of cost-benefit optimality was promoted.

Thirty years on, it is clear that the debate on the welfare state has largely turned to the advantage of the proponents of economic efficiency, who have succeeded in convincing those in powerespecially in Europe where it was bornthat social protection is a burden rather than a boon.

This does not mean that the principles of the welfare state have become obsolete or that the resulting public policies have ceased to be effective and just. Rather, a simplistic vision of the functioning of the economy, which opposes a predatory state to a liberating market, has come to dominate public debate.

From this point of view, a speech by the French president, Emmanuel Macron, on March 12th, amid the shock of the Covid-19 health crisis, appeared as an epiphany as radical as it was late: What this pandemic is already revealing is that free health care, without condition of income, course or profession, our welfare state, are not costs or burdens, but precious goods, essential assets when fate strikes There are goods and services which must be placed outside the laws of the market.

All of this is true. It is also diametrically opposed to the policy conducted in France since the 2017 presidential election and during the previous mandate, when Macron exerted a considerable influence on the dismal presidency of Franois Hollande. It is also not precise enough. If fate strikes humanity today, it does not fall from heaven: humans, in the age of the environmental crises of the Anthropocene, have become the source of their own fatality.

The decade that is opening is indeed that of the ecological challenge: faced with climate change, the destruction of biodiversity and the degradation of ecosystemsvisible and tangible everywhere on the planethuman communities must initiate a profound transformation of attitudes and behaviours to prevent the 21st century being one of self-destruction of human wellbeing. The first months of the first year of this decisive decade leave little doubt about the urgency of this collective effort.

As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house, big advertising partners or a multi-million euro enterprise. For the longevity of Social Europe we depend on our loyal readers - we depend on you.

First, Australia was ravaged by a succession of giant fires, which only rain eventually extinguished. Then the Covid-19 pandemic rendered inactive almost half of humanity and, with that, the global economy. Yet the worldwide health crisis is, at its origin, ecological: this virusas before it SARS, MERS, Ebola and to some extent HIV-AIDSis a pathology of the human-animal frontier. It is because humans have gone too far in the destruction of ecosystems, the conquest of biodiversity and the commodification of life that they are today affected, panicked and paralysedin other words conquered in turn.

Faced with these ecological crises, for which we are fully responsible, we need to rediscover the equalising power of the welfare state, which alone can transform uncertainty into risk, hazard into protection, chance into justice. In short, we must mutualise social risks to reduce them in the name of human wellbeingstarting with health, the key interface between people and ecosystems.

This is where the concept of the social-ecological state comes in. An extension of the genius of the welfare state, its guiding principle is denaturalisationor, put positively, socialisation. This entails transforming ecological uncertainty into social risk, by means of public guarantees and insurance, to make the social consequences of the environmental crises of the 21st century as fair as possible and therefore, in principle, mitigate their natural violence.

But, as with the welfare state, this principle varies widely from one country to anotherindeed from one region to anotheras regards the demand and capacity for socialisation. Different social-ecological state systems are thus emerging, according to at least three criteria: vulnerability (exposure to risks, state of health of the population and so on), protection (development of social protections, degree of social inequality, etcetera) and resilience (social cohesion, trust, quality of institutions). Using these three criteria, four different regimes appear on the planetfour worlds of the social-ecological state seem to emerge.

Bio-techno power is the first such world. What Michel Foucault called half a century ago the power over life is today combined with digital-control tools whose omnipotence he could not imagine. In the beginnings of the Covid-19 crisis, a mode of socialisation of environmental crises emerged which combines strong exposure to risk, authoritarian power, civil discipline and digital surveillance.

South Korea is the most emblematic country of this model but China has prefigured and applied it on a larger scale. The admiration for this social-ecological regimepalpable in European countries whose populations are considered less reliable and governments deemed too laxdisregards what ecological authoritarianism has cost the whole world: the initial alerts on what was then only a regional epidemic were fiercely repressed by the Chinese autocracy in the autumn of 2019. The effectiveness of bio-techno power is thus doubly doubtful, from the factual and the ethical point of view.

The second world is that of ecological neoliberalism. In Brazil, the United States and Australia, market fundamentalism takes the place of social-ecological policy. Environmental regulations as well as health protections are weakened in favor of a small minority who have captured political power and exploited it as a source of rents, to extract huge profits from health privatisation and environmental degradation. Yet, in these countries, exposure to environmental risks is high and collective protection is already weak and fragile, as the unfolding health tragedy in the US makes clear. The political development of Australia in the coming years will be a good indicator of the viability of ecological neoliberalism.

Economic naturalism appears as the third world of the social-ecological state and it is the prerogative of European countries. Unable to define together a new social-ecological regime calibrated for the 21st century, they have opted for a naturalisation of the economic system they have built in common since the 1950snotions borrowed from the living world, such as growth and competition, ending up governing human societies and social systems. We can see today how secondary these superficial economic realities are, conditioned by human wealth and social co-operation.

The health crisis triggered by Covid-19 hit the French healthcare system, for instance, at the exact moment when political powernot globalisation nor demographic ageingwas pushing it, knowingly, to its breaking point. The national madness of the budgetary rationalisation of the social system is the reflection of European rules which seem to have as their objective collective ill-being.

The fourth and last world of the social-ecological state is that of natural regulations. Even if the welfare state were to continue its global expansion, it still encompasses only 30 per cent of humanity. In most of Africa and Asia, human communities simultaneously face very high exposure to environmental risk while enjoying very little social protection. Take India, where annual health spending per capita is around $60 (70 times lower than that of OECD countries).

Humans there need to rely mostly if not solely on natural protections, such as the heat, varying with the seasons, with its power to destroy many viruses. More generally, the regulatory services provided by ecosystems protect humans: climate regulation, purification of air and water, tsunami mitigation, destruction of parasites and pathogens, and so on. These natural regulations, more or less degraded by humans since the industrial revolution, are in India both enemies and allies, with heat waves appearing when viruses are absent and mangroves protecting land submerged by human-induced climate change.

The major difference between this rudimentary typology and that, much more sophisticated, of Esping-Andersen is in its temporality: Esping-Andersen conceived his Weberian ideal types after a century of evolution of the welfare state, while a strong path dependency had helped stabilise its different regimes. The four worlds of the social-ecological state, as we can see them today, are still in their infancy. Far from being crystallised, their internal contradictions will make them evolve rapidly.

In fact, as with the nascent welfare state of the late 19th century, the social-ecological state remains largely to be invented. From this point of view, the Covid-19 crisis is not an opportunityit has neither interest nor merit nor virtue. It is a human disaster whose response breeds another human disaster.

But there are consequences of this crisis from which we can hope to draw useful lessons for the future, to avoid further shocks and to mitigate the shocks we cannot avoid. One of these is that human communities around the world have converged at staggering speed towards the underlying universal value of humanity, revealing that their common priority is health and not economic growth. We are hence called to a double revolution: putting health back at the heart of our public policies, while putting the environment at the heart of our health policies.

See the rest here:
The four worlds of the social-ecological state - Social Europe

Theres a New Healthy, High Protein Vegan Meat Designed for Flexitarians – LIVEKINDLY

Consumers are becoming increasingly more aware of how their food choices impact the environment and their health.

Research shows the consumption of animal products, like processed and red meat, increases the risk of certain health issues. These include heart disease, stroke, and diabetes. One study out of the University of California, Davis, found 75 percent of people have considered giving up meat for their health.

In lieu of animal products, many consumers are opting for less meat in favor of healthier, plant-based proteins. Los Angeles-based company Longve is one brand thats harnessing the power of plants to make healthier meats.

The companys CEO, Douglas Kantner, says turning 50 was a major catalyst in his health journey and ultimately inspired the companys mission and concept.

Ive always been interested in health and fitness, and have been a lifelong athleteI played football in college, he said. But when I hit 50, I found myself becoming more and more interested in what I could do to prolong my longevity.

Longve, which is a play on longevity, is revolutionizing the clean-eating market with its debut products: Gluten-Free Breadless Crumbs and Plant-Based Protein Crumblesboth of which are made from 100 percent sustainable pea protein.

Founded in 2019, Longve set out to create innovative, plant-based foods that aligned with consumers desire for good health, overall wellness, and longevity for not only themselves but for the planet, too.

With the tagline Eat for a Better Tomorrow, Today, Longve developed the worlds first shelf-stable, plant-based meat crumbles using pure-plant ingredients.

After working in the food industry for more than 30 years I decided to use my industry experience to find ways to help people find a way to put more plants on their plates, Kantner explained.

He continued, I wanted them to actually enjoy products that were plant-based, clean label and had nutritional value in a way that was more pleasurable than punishing, while also keeping an eye on planet sustainability.

The plant-based demographic has greatly expanded as more people adopt flexible eating habits. Health concerns, as well as environmental factors, have driven the popularity of the flexitarian diet.

Flexitarianismalso called the semi-vegetarian dietpromotes the consumption of plant-based foods. A flexitarian diet typically consists of vegetables, fruits, legumes, and whole grains. But it isnt as strict as vegetarian and vegan diets. So, proponents of flexitarianism may still eat animal products like meat and fish, but only in moderation.

Along with wanting to create foods that are healthy and good for the planet, the notion of flexible eating also inspires the Longve team. But they believe the definition of flexitarianism should expand to include people who simply want to eat more vegetables.

Although the companys products are plant-based, it doesnt just cater to non-meat eaters. It says it made its products to support all dietary choices and lifestyles. One of its missions is to help people achieve their health goals in the cleanest, most efficient way possible.

Longves goal is to help people easily transition to eating more plant-based foodsa goal that Kantner says the companys clean, healthy products will help them achieve.

All of our products are clean label and made with minimal ingredients and no additives. We use 100-percent sustainable pea protein as the sole ingredient in our Plant-based Protein Crumbles and Plant-Based Breadless Crumbs, and were extremely proud of the fact that theyre Project Non-GMO Certified, Certified Gluten-Free, NSF-certified Plant-Based, and soy-free, he said. That makes them one of the cleanest meat replacements on the market, and a great foundation for any flexitarian diet.

Pea protein is becoming increasingly more popular amongst manufacturers like Longve because the protein source is plant-based, better for the environment, and more economical to produce.

Pea protein is obtained from ground yellow split peas. It is a more favorable plant-based protein source because it doesnt contain common food allergens like soy or wheat. It also features a good profile of nutrients like fiber, folate, manganese, phosphorus, niacin, and copper.

Pea protein is also a complete protein. This is because it contains all nine amino acids that are essential for the human diet.

Longves plant-based ground crumbles not only taste realistic but have a similar texture to traditional ground meat.

The reaction to our Original Plant-based Protein Crumbles [has been] incrediblelots of people love the fact that [the crumbles] neutral flavor makes them a great base for their favorite recipes, Kantner said.

The CEO explained that the favorable response to the original crumbles led the company to launch two new flavors. They also created a Chopped Protein product designed to replace chopped poultry and pork in recipes.

We did, however, have lots of requests for flavored crumbles that would make it even easier to get dinner on the table during busy weeknights. Were really excited to [introduce] two flavored crumblesMasala Curry and Fiesta Tacolater this summer. Both [crumbles] come with seasoning packets to make preparation a snap. We will also be launching Chopped Protein which will replace white meats like Turkey and Pork, he said.

If the companys Instagram is anything to go by, its products are extremely versatile. It showcases the Plant-Based Protein Crumbles in a variety of dishes. These include chilis, enchilada lasagnas, tacos, and meaty spaghetti, to name a few

Chef Lee Gross says the products ease of use makes adding high-quality plant protein into dishes a breeze.

[The crumbles] can be used in a virtually endless range of applications, adaptable to almost any cuisine or cooking style I can think of. Prep is a breeze, requiring only a quick soak to be recipe-ready with a distinctive, meat-like texture, and can even be used straight from the bag in dishes such as soups and stews, he said.

The crumbles also stack up well to ground beef. One six-ounce bag of Plant-Based Protein Crumbles offers roughly the equivalent of three pounds of traditional ground meat. The crumbles also feature a high protein content. A single serving of Longves nutritious, pea protein-based Original variety contains 40 grams of protein. The Fiesta Taco and Masala Curry crumbles contain 41 and 44 grams of protein per serving, respectively.

Longves three varieties of shelf-stable Plant-Based Protein Crumbles are available to order on Amazon. Its Gluten-Free Breadless Crumbswhich come in two varieties: Panko and Plaincan also be purchased online.

To learn more about Longve, visit LongeveBrands.com.

This is a sponsored post.

Summary

Article Name

There's a New Healthy, High Protein Vegan Meat Designed for Flexitarians

Description

Flexitarians just got more vegan meat options. The plant-based company Longve is revolutionizing the clean-eating market using pea protein.

Author

Audrey Enjoli

Publisher Name

LIVEKINDLY

Publisher Logo

See more here:
Theres a New Healthy, High Protein Vegan Meat Designed for Flexitarians - LIVEKINDLY

Covid-19: US governments aid agency announces additional $3 million grant for India – Scroll.in

The United States Agency for International Development, or USAID, has announced an additional grant of $3 million (Rs 22.54 crore) to India to help it combat Covid-19. USAID has so far granted India $5.9 million (Rs 43.59 crore). It had granted $2.9 million (Rs 21.79 crore) to India on April 6.

This additional funding represents our commitment to building a safer and healthier world, United States Ambassador to India Kenneth Juster tweeted on Thursday. The United States government will provide the funds through USAID.

A press release from the US embassy said that the aid will be provided through Partnerships for Affordable Healthcare Access and Longevity project, a financing platform established by IPE Global, an Indian international development consulting group.

This additional funding to support India in its continuing efforts to combat Covid-19 is yet another example of the strong and enduring partnership between the United States and India, Juster said according to the press release.

The embassy added that the United States has through USAID and Department of Health and Human Services agencies, provided India over $1.4 billion (Rs 10,525 crore) in health assistance and nearly $2.8 billion (Rs 21,050 crore) in total assistance over the last 20 years.

India has so far reported 33,050 cases of Covid-19, including 1,074 deaths, according to the Ministry of Health and Family Welfare. On March 26, the Narendra Modi-led government announced an economic bailout package worth Rs 1.7 lakh crore to help the poor tide over the impact of the countrywide lockdown, that is in place to combat Covid-19. The lockdown has been extended till May 3.

Follow live updates on the coronavirus pandemic

Link:
Covid-19: US governments aid agency announces additional $3 million grant for India - Scroll.in